ABCL:NSD-AbCellera Biologics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 27.67

Change

-1.42 (-4.88)%

Market Cap

USD 7.88B

Volume

0.78M

Average Target Price

USD 53.78 (+94.35%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Company Website : http://www.abcellera.com

Address : 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1

Employees : 206

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 71.91

Short Ratio : 3.87

52 Week Low : 23.20

Shorted Shares : 5,901,253

200 Day Moving Average : 37.86

Shorted Shares Previous Month : 6,198,393

50 Day Moving Average : 28.73

Shares Held By Insiders : 325.43%

Short Percentage : 2.00%

Shares Held by Institutions : 36.88%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

 USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

 USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

 USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

 USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

 USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

 USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

 USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

 USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

 USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ABCL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.24% 19% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.24% 19% F 9% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 7.88B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3,270.41 0% N/A 0% N/A
Price/Book Ratio 9.36 23% F 18% F
Price / Cash Flow Ratio 347.34 0% N/A 2% F
EV/EBITDA 42.38 17% F 23% F
Management Effectiveness  
Return on Equity 28.29% 98% A+ 93% A
Return on Invested Capital 29.62% 93% A 95% A
Return on Assets 19.18% 99% A+ 99% A+
Debt to Equity Ratio 0.26% 82% B- 91% A-
Technical Ratios  
Short Ratio 3.87 50% F 34% F
Short Percent 6.38% 52% F 33% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.